Results 171 to 180 of about 73,583 (263)

Purpura Fulminans in a Patient With Cirrhosis and Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia: Diagnostic Challenges in Coagulopathy. [PDF]

Cureus
White DD, Blaise K, Dartez TL, Carbajal A, Bienvenue M, Wexler C, Chedid C.   +6 more
europepmc   +1 more source

Pharmacological activation of NO‐cGMP signalling attenuates metabolic dysfunction‐associated steatohepatitis

British Journal of Pharmacology, EarlyView.
Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth, Malte Roessing, Moritz Lehners, Lisa Dietz, Anja Schmitt, Stephan Hailfinger, Andreas Peter, Leticia Quintanilla‐Martinez, Irene Gonzalez‐Menendez, Ingmar Mederacke, German Ott, Peter Sandner, Matthias Schwab, Robert Feil, Susanne Feil   +14 more
wiley   +1 more source

Risk factors for rebleeding at different time points after TIPS in cirrhotic patients with AEVB: A case-control study. [PDF]

Medicine (Baltimore)
Tan C, Yao W, Su H, Xie J, Ma R, Huang L.   +5 more
europepmc   +1 more source

Transcriptomic and metabolomic analyses reveal that lobeglitazone ameliorates hepatic steatosis in rats concurrent with regulation of mitochondrial pyruvate metabolism

British Journal of Pharmacology, EarlyView.
Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang, Su Young Son, Youngmi Song, Hyewon Choi, In‐Gu Do, Choong Hwan Lee, Cheol‐Young Park   +6 more
wiley   +1 more source

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response

Cancer Science, EarlyView.
Hypericin induces autophagic AKT degradation by promoting AKT‐HSPA5 interaction in an S473 phosphorylation‐dependent manner, suppressing HCC growth. It enhances CD8+ T cell‐mediated antitumor immunity and synergizes with anti‐PD‐L1 therapy, showing favorable safety for HCC treatment. ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary
Sien Ma, Qianqian Xu, Mengjuan Zhu, Xianming Ge, Jian Xu, Yan Pan, Mengli Wang, Yuting Zhu, Aoxuan Xu, Hanmeng Liu, GuangHai Xiang, Weipeng Gong, Bao Zhao   +12 more
wiley   +1 more source

Smoldering Amiodarone-Induced Decompensated Cirrhosis: Cumulative Dose-Related Toxicity. [PDF]

Case Rep Gastrointest Med
Ta J, Bhandari R, Di Francesco J, Roberts A, Long E, Chhabra P, Beig J.   +6 more
europepmc   +1 more source

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

Post-ERCP Outcomes in Cirrhotic Patients With Thrombocytopenia: A Propensity-Matched Retrospective Comparative Analysis on TriNetX Health Research Database. [PDF]

JGH Open
Hayat U, Hussain A, Ali H, Yagnik KJ, Patel P, Siddiqui AA, Inamdar S, Qureshi K, Khara HS, Confer B, Diehl DL.   +10 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

ROLE OF STATINS IN CIRRHOTIC PORTAL HYPERTENSION: META-ANALYSIS OF RANDOMIZED STUDIES. [PDF]

Arq Gastroenterol
Moreno MOA, Paz CLDSL, Rodrigues MAN, Andrade ACD, Dezan MGF, Cavalcante LN, Lyra AC.   +6 more
europepmc   +1 more source